Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

June 7, 2024

https://www.globenewswire.com/news-release/2024/06/07/2895351/0/en/Silo-Pharma-Announces-Successful-Production-of-its-SP-26-Ketamine-Implant-for-Fibromyalgia.html

Analytical testing has confirmed optimal formulation for upcoming studies

SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq:SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company’s SP-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.